The long pentraxin PTX3: A prototypical sensor of tissue injury and a regulator of homeostasis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Tissue damage frequently occurs. The immune system senses it and enforces homeostatic responses that lead to regeneration and repair. The synthesis of acute phase molecules is emerging as a crucial event in this program. The prototypic long pentraxin PTX3 orchestrates the recruitment of leukocytes, stabilizes the provisional matrix in order to facilitate leukocyte and stem progenitor cells trafficking, promotes swift and safe clearance of dying cells and of autoantigens, limiting autoimmunity and protecting the vasculature. These non-redundant actions of PTX3 are necessary for the resolution of inflammation. Recent studies have highlighted the mechanisms by which PTX3 adapts the functions of innate immune cells, orchestrates tissue repair and contributes to select the appropriate acquired immune response in various tissues. Conversely, PTX3 continues to be produced in diseases where the inflammatory response does not resolve. It is therefore a valuable biomarker for more precise and personalized stratification of patients, often independently predicting clinical evolution and outcome. There is strong promise for novel therapies based on understanding the mechanisms with which PTX3 plays its homeostatic role, especially in regulating leukocyte migration and the resolution of inflammatory processes. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Original languageEnglish
Pages (from-to)112-125
Number of pages14
JournalImmunological Reviews
Volume280
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Nuclear Family
Homeostasis
Leukocytes
Wounds and Injuries
Stem Cells
Autoantigens
Autoimmunity
Regeneration
Immune System
Biomarkers
Inflammation
Therapeutics

Cite this

@article{6848215ce5e44897aaa797677afea33c,
title = "The long pentraxin PTX3: A prototypical sensor of tissue injury and a regulator of homeostasis",
abstract = "{\circledC} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Tissue damage frequently occurs. The immune system senses it and enforces homeostatic responses that lead to regeneration and repair. The synthesis of acute phase molecules is emerging as a crucial event in this program. The prototypic long pentraxin PTX3 orchestrates the recruitment of leukocytes, stabilizes the provisional matrix in order to facilitate leukocyte and stem progenitor cells trafficking, promotes swift and safe clearance of dying cells and of autoantigens, limiting autoimmunity and protecting the vasculature. These non-redundant actions of PTX3 are necessary for the resolution of inflammation. Recent studies have highlighted the mechanisms by which PTX3 adapts the functions of innate immune cells, orchestrates tissue repair and contributes to select the appropriate acquired immune response in various tissues. Conversely, PTX3 continues to be produced in diseases where the inflammatory response does not resolve. It is therefore a valuable biomarker for more precise and personalized stratification of patients, often independently predicting clinical evolution and outcome. There is strong promise for novel therapies based on understanding the mechanisms with which PTX3 plays its homeostatic role, especially in regulating leukocyte migration and the resolution of inflammatory processes. {\circledC} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
author = "M Erreni and AA Manfredi and C Garlanda and A Mantovani and P Rovere-Querini",
year = "2017",
doi = "10.1111/imr.12570",
language = "English",
volume = "280",
pages = "112--125",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The long pentraxin PTX3: A prototypical sensor of tissue injury and a regulator of homeostasis

AU - Erreni, M

AU - Manfredi, AA

AU - Garlanda, C

AU - Mantovani, A

AU - Rovere-Querini, P

PY - 2017

Y1 - 2017

N2 - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Tissue damage frequently occurs. The immune system senses it and enforces homeostatic responses that lead to regeneration and repair. The synthesis of acute phase molecules is emerging as a crucial event in this program. The prototypic long pentraxin PTX3 orchestrates the recruitment of leukocytes, stabilizes the provisional matrix in order to facilitate leukocyte and stem progenitor cells trafficking, promotes swift and safe clearance of dying cells and of autoantigens, limiting autoimmunity and protecting the vasculature. These non-redundant actions of PTX3 are necessary for the resolution of inflammation. Recent studies have highlighted the mechanisms by which PTX3 adapts the functions of innate immune cells, orchestrates tissue repair and contributes to select the appropriate acquired immune response in various tissues. Conversely, PTX3 continues to be produced in diseases where the inflammatory response does not resolve. It is therefore a valuable biomarker for more precise and personalized stratification of patients, often independently predicting clinical evolution and outcome. There is strong promise for novel therapies based on understanding the mechanisms with which PTX3 plays its homeostatic role, especially in regulating leukocyte migration and the resolution of inflammatory processes. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

AB - © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Tissue damage frequently occurs. The immune system senses it and enforces homeostatic responses that lead to regeneration and repair. The synthesis of acute phase molecules is emerging as a crucial event in this program. The prototypic long pentraxin PTX3 orchestrates the recruitment of leukocytes, stabilizes the provisional matrix in order to facilitate leukocyte and stem progenitor cells trafficking, promotes swift and safe clearance of dying cells and of autoantigens, limiting autoimmunity and protecting the vasculature. These non-redundant actions of PTX3 are necessary for the resolution of inflammation. Recent studies have highlighted the mechanisms by which PTX3 adapts the functions of innate immune cells, orchestrates tissue repair and contributes to select the appropriate acquired immune response in various tissues. Conversely, PTX3 continues to be produced in diseases where the inflammatory response does not resolve. It is therefore a valuable biomarker for more precise and personalized stratification of patients, often independently predicting clinical evolution and outcome. There is strong promise for novel therapies based on understanding the mechanisms with which PTX3 plays its homeostatic role, especially in regulating leukocyte migration and the resolution of inflammatory processes. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

U2 - 10.1111/imr.12570

DO - 10.1111/imr.12570

M3 - Article

VL - 280

SP - 112

EP - 125

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -